FDA approves new bladder cancer treatment while regulatory leadership faces transition, as medical debates emerge on hyponatremia correction and menopause management strategies.

FDA has approved ctDNA-guided atezolizumab for bladder cancer, marking the first approval in this indication since a 2022 withdrawal of accelerated approval for urothelial carcinoma, offering renewed treatment options for patients.

A meningococcal B vaccine catch-up program is being called for young adults following a student death in a Reading area outbreak, highlighting gaps in meningitis B immunization coverage among adults.

Medical debate is intensifying over hyponatremia correction rates, with recent data suggesting rapid serum sodium correction may yield better outcomes despite traditional guidelines recommending slow correction to avoid osmotic demyelination.

Women with abdominal obesity experience a higher burden of menopausal symptoms and display distinct patterns of symptom relationships compared to women without abdominal obesity, suggesting obesity type matters in menopause management.

Eye movement biomarkers detected through video oculography show promise in early detection of atypical Alzheimer's disease, advancing the role of ocular assessments in neurodegeneration screening.

The FDA's Drug Center head is expected to depart following the commissioner's exit, signaling leadership transitions within the regulatory agency.

Analysis reveals that fewer than one in five anticancer drugs entering pediatric clinical trials advance to phase 3 trials, with even fewer earning pediatric regulatory approval, highlighting development challenges in pediatric oncology.

New trial data demonstrate that some patients can maintain meaningful weight loss after reducing tirzepatide from maximum dose, potentially offering a more sustainable approach to weight management therapy.